ID   Caco-2
AC   CVCL_0025
SY   CaCo-2; CACO-2; Caco 2; CACO 2; CACO2; CaCo2; CaCO2; Caco2; Caco-2/ATCC; Caco-II
DR   BTO; BTO:0000195
DR   CLO; CLO_0002172
DR   CLO; CLO_0050627
DR   EFO; EFO_0001099
DR   MCCL; MCC:0000120
DR   CLDB; cl614
DR   CLDB; cl615
DR   CLDB; cl616
DR   CLDB; cl617
DR   CLDB; cl618
DR   CLDB; cl619
DR   CLDB; cl621
DR   CLDB; cl5174
DR   Abcam; ab275464
DR   AddexBio; C0009009/29
DR   ArrayExpress; E-MTAB-2706
DR   BCRJ; 0059
DR   BioSample; SAMN03473140
DR   BioSample; SAMN05292461
DR   BioSample; SAMN10989600
DR   cancercelllines; CVCL_0025
DR   CCRID; 1101HUM-PUMC000100
DR   CCRID; 1102HUM-NIFDC00087
DR   CCRID; 3101HUMTCHu146
DR   CCRID; 4201HUM-CCTCC00153
DR   CCRID; 5301HUM-KCB07010YJ
DR   Cell_Model_Passport; SIDM00891
DR   ChEMBL-Cells; CHEMBL3307519
DR   ChEMBL-Targets; CHEMBL614058
DR   CLS; 300137
DR   ColonAtlas; CACO2
DR   Cosmic; 720340
DR   Cosmic; 873696
DR   Cosmic; 875297
DR   Cosmic; 876709
DR   Cosmic; 887244
DR   Cosmic; 889531
DR   Cosmic; 948127
DR   Cosmic; 948829
DR   Cosmic; 983736
DR   Cosmic; 995392
DR   Cosmic; 1043805
DR   Cosmic; 1122320
DR   Cosmic; 1132564
DR   Cosmic; 1132694
DR   Cosmic; 1184081
DR   Cosmic; 1187299
DR   Cosmic; 1310931
DR   Cosmic; 1466811
DR   Cosmic; 1479620
DR   Cosmic; 1524334
DR   Cosmic; 1552180
DR   Cosmic; 1676742
DR   Cosmic; 1708415
DR   Cosmic; 1803940
DR   Cosmic; 1933015
DR   Cosmic; 2036652
DR   Cosmic; 2145574
DR   Cosmic; 2156940
DR   Cosmic; 2301543
DR   Cosmic; 2301964
DR   Cosmic; 2667879
DR   Cosmic; 2800568
DR   DepMap; ACH-000003
DR   DSMZ; ACC-169
DR   DSMZCellDive; ACC-169
DR   ECACC; 09042001
DR   ECACC; 86010202
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   FCS-free; 192-2-378-1-3-3
DR   GEO; GSM206450
DR   GEO; GSM274711
DR   GEO; GSM274712
DR   GEO; GSM274725
DR   GEO; GSM383861
DR   GEO; GSM472900
DR   GEO; GSM472933
DR   GEO; GSM513908
DR   GEO; GSM514182
DR   GEO; GSM741244
DR   GEO; GSM749689
DR   GEO; GSM749691
DR   GEO; GSM749748
DR   GEO; GSM784006
DR   GEO; GSM845394
DR   GEO; GSM843481
DR   GEO; GSM843482
DR   GEO; GSM945162
DR   GEO; GSM945203
DR   GEO; GSM945206
DR   GEO; GSM945236
DR   GEO; GSM1006210
DR   GEO; GSM1006211
DR   GEO; GSM1006212
DR   GEO; GSM1346866
DR   GEO; GSM1374426
DR   GEO; GSM1448160
DR   GEO; GSM2549989
DR   IARC_TP53; 21749
DR   IBRC; C10094
DR   ICLC; HTL97023
DR   KCB; KCB 200710YJ
DR   KCLB; 30037.1
DR   Lonza; 36
DR   MeSH; D018938
DR   MetaboLights; MTBLS227
DR   MetaboLights; MTBLS328
DR   NCBI_Iran; C139
DR   PharmacoDB; Caco2_161_2019
DR   PRIDE; PXD001550
DR   PRIDE; PXD005354
DR   PRIDE; PXD005355
DR   PRIDE; PXD018357
DR   PRIDE; PXD019645
DR   PRIDE; PXD023760
DR   Progenetix; CVCL_0025
DR   PubChem_Cell_line; CVCL_0025
DR   RCB; RCB0988
DR   TOKU-E; 762
DR   Ubigene; YC-D003
DR   Wikidata; Q5016050
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=2914637;
RX   PubMed=3349466;
RX   PubMed=3518877;
RX   PubMed=6935474;
RX   PubMed=7459858;
RX   PubMed=7764660;
RX   PubMed=8253353;
RX   PubMed=8508948;
RX   PubMed=9294210;
RX   PubMed=10092214;
RX   PubMed=10612807;
RX   PubMed=10737795;
RX   PubMed=11414198;
RX   PubMed=11416159;
RX   PubMed=11668190;
RX   PubMed=12584437;
RX   PubMed=14599474;
RX   PubMed=15316659;
RX   PubMed=15731278;
RX   PubMed=15868485;
RX   PubMed=16418264;
RX   PubMed=16854228;
RX   PubMed=18258742;
RX   PubMed=20570890;
RX   PubMed=20606684;
RX   PubMed=20831567;
RX   PubMed=21607810;
RX   PubMed=23272949;
RX   PubMed=23932154;
RX   PubMed=24042735;
RX   PubMed=24755471;
RX   PubMed=25485619;
RX   PubMed=25841592;
RX   PubMed=25877200;
RX   PubMed=25926053;
RX   PubMed=25944804;
RX   PubMed=25960936;
RX   PubMed=26537799;
RX   PubMed=26589293;
RX   PubMed=26869432;
RX   PubMed=28196595;
RX   PubMed=28683746;
RX   PubMed=29101300;
RX   PubMed=29787057;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31981602;
RX   PubMed=33389257;
RX   PubMed=34339474;
CC   Part of: AstraZeneca Colorectal cell line (AZCL) panel.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: ENCODE project common cell types; tier 3.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Virology: Highly susceptible to infection by SARS coronavirus (SARS-CoV) (PubMed=15316659; PubMed=15731278).
CC   Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257; PubMed=34339474).
CC   Doubling time: 51.41 hours (PubMed=25944804); 3-4 days (ATCC=HTB-37); ~60-70 hours (CLS=300137); ~80 hours (DSMZ=ACC-169); ~32 hours (PBCF).
CC   HLA typing: A*02:01,02:01; B*15:05,56/39; C*04:01,04:01 (PubMed=25960936).
CC   HLA typing: A*02:01,02:01; B*15:01,15:01; C*04:01,04:01 (PubMed=26589293).
CC   HLA typing: A*02:01:01; B*15:01:01; C*04:01:01; DPB1*04:01:01; DQA1*03:01:01; DQB1*03:02:01; DRB1*04:04:01 (CLS=300137).
CC   Microsatellite instability: Stable (MSS) (PubMed=24042735; PubMed=24755471; PubMed=25926053; PubMed=28683746).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (PubMed=24755471; DepMap=ACH-000003).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (PubMed=9294210).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (PubMed=24755471; DepMap=ACH-000003).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (PubMed=16418264; PubMed=24755471; PubMed=28683746; DepMap=ACH-000003).
CC   Omics: CTCF ChIP-seq epigenome analysis.
CC   Omics: H3K27me3 ChIP-seq epigenome analysis.
CC   Omics: H3K36me3 ChIP-seq epigenome analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep phosphoproteome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: N-glycan profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).
CC   Genome ancestry: African=3.33%; Native American=0%; East Asian, North=4.59%; East Asian, South=0%; South Asian=0%; European, North=47.35%; European, South=44.73% (PubMed=30894373).
CC   Discontinued: Abcam; ab275464; true.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
ST   Source(s): AddexBio=C0009009/29; ATCC=HTB-37; CCRID; CLS=300137; DSMZ=ACC-169; ECACC=09042001; ECACC=86010202; PubMed=11416159; PubMed=25877200; PubMed=25926053; RCB=RCB0988
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D10S1248: 13,15
ST   D12S391: 17,23
ST   D13S317: 11,13,14
ST   D16S539: 12,13
ST   D18S51: 12
ST   D19S433: 15
ST   D1S1656: 15,16
ST   D21S11: 30 (DSMZ=ACC-169; PubMed=11416159; PubMed=25877200)
ST   D21S11: 30,32 (ATCC=HTB-37; CCRID; CLS=300137; PubMed=25926053)
ST   D22S1045: 15,16
ST   D2S1338: 17,25
ST   D3S1358: 14,17
ST   D5S818: 12,13
ST   D7S820: 11,12 (ATCC=HTB-37; CCRID; CLS=300137; DSMZ=ACC-169; ECACC=09042001; ECACC=86010202; PubMed=25877200; PubMed=25926053; RCB=RCB0988)
ST   D7S820: 12 (AddexBio=C0009009/29)
ST   D8S1179: 12 (DSMZ=ACC-169; PubMed=11416159)
ST   D8S1179: 12,14 (ATCC=HTB-37; CCRID; CLS=300137; PubMed=25877200)
ST   FGA: 19
ST   Penta D: 9 (DSMZ=ACC-169)
ST   Penta D: 9,11 (ATCC=HTB-37; PubMed=25877200)
ST   Penta E: 7
ST   SE33: 21
ST   TH01: 6
ST   TPOX: 9,11
ST   vWA: 16,18
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   72Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 49
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
RX   PubMed=2914637; DOI=10.1016/0016-5085(89)90897-4;
RA   Hidalgo I.J., Raub T.J., Borchardt R.T.;
RT   "Characterization of the human colon carcinoma cell line (Caco-2) as a
RT   model system for intestinal epithelial permeability.";
RL   Gastroenterology 96:736-749(1989).
RX   PubMed=3349466;
RA   Chantret I., Barbat A., Dussaulx E., Brattain M.G., Zweibaum A.;
RT   "Epithelial polarity, villin expression, and enterocytic
RT   differentiation of cultured human colon carcinoma cells: a survey of
RT   twenty cell lines.";
RL   Cancer Res. 48:1936-1942(1988).
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
RX   PubMed=7764660; DOI=10.1007/BF00749813;
RA   Hashimoto K., Shimizu M.;
RT   "Epithelial properties of human intestinal Caco-2 cells cultured in a
RT   serum-free medium.";
RL   Cytotechnology 13:175-184(1993).
RX   PubMed=8253353; DOI=10.1016/0016-5085(93)91076-t;
RA   Chastre E., Empereur S., Di Gioia Y., El Mahdani N., Mareel M.M.,
RA   Vleminckx K.L., Van Roy F.M., Bex V., Emami S., Spandidos D.A.,
RA   Gespach C.;
RT   "Neoplastic progression of human and rat intestinal cell lines after
RT   transfer of the ras and polyoma middle T oncogenes.";
RL   Gastroenterology 105:1776-1789(1993).
RX   PubMed=8508948; DOI=10.1111/j.1432-0436.1993.tb00645.x;
RA   de Bruine A.P., de Vries J.E., Dinjens W.N.M., Moerkerk P.T.M.,
RA   van der Linden E.P.M., Pijls M.M.J., ten Kate J., Bosman F.T.;
RT   "Human Caco-2 cells transfected with c-Ha-Ras as a model for endocrine
RT   differentiation in the large intestine.";
RL   Differentiation 53:51-60(1993).
RX   PubMed=9294210; DOI=10.1073/pnas.94.19.10330;
RA   Ilyas M., Tomlinson I.P.M., Rowan A.J., Pignatelli M., Bodmer W.F.;
RT   "Beta-catenin mutations in cell lines established from human
RT   colorectal cancers.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:10330-10334(1997).
RX   PubMed=10092214; DOI=10.1002/(SICI)1097-4652(199812)177:4<618::AID-JCP12>3.0.CO;2-R;
RA   Levy P., Robin H., Kornprobst M., Capeau J., Cherqui G.;
RT   "Enterocytic differentiation of the human Caco-2 cell line correlates
RT   with alterations in integrin signaling.";
RL   J. Cell. Physiol. 177:618-627(1998).
RX   PubMed=10612807; DOI=10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P;
RA   Ghadimi B.M., Sackett D.L., Difilippantonio M.J., Schrock E.,
RA   Neumann T., Jauho A., Auer G., Ried T.;
RT   "Centrosome amplification and instability occurs exclusively in
RT   aneuploid, but not in diploid colorectal cancer cell lines, and
RT   correlates with numerical chromosomal aberrations.";
RL   Genes Chromosomes Cancer 27:183-190(2000).
RX   PubMed=10737795; DOI=10.1073/pnas.97.7.3352;
RA   Rowan A.J., Lamlum H., Ilyas M., Wheeler J., Straub J.,
RA   Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.;
RT   "APC mutations in sporadic colorectal tumors: a mutational 'hotspot'
RT   and interdependence of the 'two hits'.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.-J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
RX   PubMed=12584437; DOI=10.1159/000068544;
RA   Melcher R., Koehler S., Steinlein C., Schmid M., Mueller C.R.,
RA   Luehrs H., Menzel T., Scheppach W., Moerk H., Scheurlen M.,
RA   Koehrle J., Al-Taie O.;
RT   "Spectral karyotype analysis of colon cancer cell lines of the tumor
RT   suppressor and mutator pathway.";
RL   Cytogenet. Genome Res. 98:22-28(2002).
RX   PubMed=14599474; DOI=10.1016/S0887-2333(03)00095-X;
RA   Ranaldi G., Consalvo R., Sambuy Y., Scarino M.L.;
RT   "Permeability characteristics of parental and clonal human intestinal
RT   Caco-2 cell lines differentiated in serum-supplemented and serum-free
RT   media.";
RL   Toxicol. In Vitro 17:761-767(2003).
RX   PubMed=15316659; DOI=10.1007/s00018-004-4222-9;
RA   Cinatl J. Jr., Hoever G., Morgenstern B., Preiser W., Vogel J.-U.,
RA   Hofmann W.-K., Bauer G., Michaelis M., Rabenau H.F., Doerr H.-W.;
RT   "Infection of cultured intestinal epithelial cells with severe acute
RT   respiratory syndrome coronavirus.";
RL   Cell. Mol. Life Sci. 61:2100-2112(2004).
RX   PubMed=15731278; DOI=10.1128/JVI.79.6.3846-3850.2005;
RA   Mossel E.C., Huang C., Narayanan K., Makino S., Tesh R.B.,
RA   Peters C.J.;
RT   "Exogenous ACE2 expression allows refractory cell lines to support
RT   severe acute respiratory syndrome coronavirus replication.";
RL   J. Virol. 79:3846-3850(2005).
RX   PubMed=15868485; DOI=10.1007/s10565-005-0085-6;
RA   Sambuy Y., De Angelis I., Ranaldi G., Scarino M.L., Stammati A.,
RA   Zucco F.;
RT   "The Caco-2 cell line as a model of the intestinal barrier: influence
RT   of cell and culture-related factors on Caco-2 cell functional
RT   characteristics.";
RL   Cell Biol. Toxicol. 21:1-26(2005).
RX   PubMed=16418264; DOI=10.1073/pnas.0510146103;
RA   Liu Y., Bodmer W.F.;
RT   "Analysis of P53 mutations and their expression in 56 colorectal
RT   cancer cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
RX   PubMed=16854228; DOI=10.1186/1476-4598-5-29;
RA   Bandres Elizalde E.M., Cubedo E., Agirre X., Malumbres R., Zarate R.,
RA   Ramirez N., Abajo A., Navarro A., Moreno I., Monzo M.,
RA   Garcia-Foncillas J.;
RT   "Identification by real-time PCR of 13 mature microRNAs differentially
RT   expressed in colorectal cancer and non-tumoral tissues.";
RL   Mol. Cancer 5:29.1-29.10(2006).
RX   PubMed=18258742; DOI=10.1073/pnas.0712176105;
RA   Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.;
RT   "Cell growth, global phosphotyrosine elevation, and c-Met
RT   phosphorylation through Src family kinases in colorectal cancer
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).
RX   PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192;
RA   Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S.,
RA   Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M.,
RA   Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M.,
RA   Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.;
RT   "Genomic and biological characterization of exon 4 KRAS mutations in
RT   human cancer.";
RL   Cancer Res. 70:5901-5911(2010).
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
RX   PubMed=20831567; DOI=10.1111/j.1582-4934.2010.01170.x;
RA   Ma Y.-L., Zhang P., Wang F., Moyer M.P., Yang J.-J., Liu Z.-H.,
RA   Peng J.-Y., Chen H.-Q., Zhou Y.-K., Liu W.-J., Qin H.-L.;
RT   "Human embryonic stem cells and metastatic colorectal cancer cells
RT   shared the common endogenous human microRNA-26b.";
RL   J. Cell. Mol. Med. 15:1941-1954(2011).
RX   PubMed=21607810; DOI=10.1208/s12248-011-9283-8;
RA   Borchardt R.T.;
RT   "Hidalgo, I.J., Raub, T.J., and Borchardt, R.T.: Characterization
RT   of the human colon carcinoma cell line (Caco-2) as a model system for
RT   intestinal epithelial permeability, Gastroenterology, 96, 736-749,
RT   1989 -- the backstory.";
RL   AAPS J. 13:323-327(2011).
RX   PubMed=23272949; DOI=10.1186/1755-8794-5-66;
RA   Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A.,
RA   Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A.,
RA   Orphanides G., French T., Wessels L.F.A.;
RT   "Subtypes of primary colorectal tumors correlate with response to
RT   targeted treatment in colorectal cell lines.";
RL   BMC Med. Genomics 5:66.1-66.15(2012).
RX   PubMed=23932154; DOI=10.1016/j.radonc.2013.06.032;
RA   Salendo J., Spitzner M., Kramer F., Zhang X., Jo P., Wolff H.A.,
RA   Kitz J., Kaulfuss S., Beissbarth T., Dobbelstein M., Ghadimi M.,
RA   Grade M., Gaedcke J.;
RT   "Identification of a microRNA expression signature for
RT   chemoradiosensitivity of colorectal cancer cells, involving
RT   miRNAs-320a, -224, -132 and let7g.";
RL   Radiother. Oncol. 108:451-457(2013).
RX   PubMed=24042735; DOI=10.1038/oncsis.2013.35;
RA   Ahmed D., Eide P.W., Eilertsen I.A., Danielsen S.A., Eknaes M.,
RA   Hektoen M., Lind G.E., Lothe R.A.;
RT   "Epigenetic and genetic features of 24 colon cancer cell lines.";
RL   Oncogenesis 2:e71.1-e71.8(2013).
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25841592; DOI=10.1016/j.jprot.2015.03.019;
RA   Piersma S.R., Knol J.C., de Reus I., Labots M., Sampadi B.K.,
RA   Pham T.V., Ishihama Y., Verheul H.M.W., Jimenez C.R.;
RT   "Feasibility of label-free phosphoproteomics and application to
RT   base-line signaling of colorectal cancer cell lines.";
RL   J. Proteomics 127:247-258(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
RX   PubMed=25944804; DOI=10.1158/1078-0432.CCR-14-2457;
RA   Bazzocco S., Dopeso H., Carton-Garcia F., Macaya I., Andretta E.,
RA   Chionh F., Rodrigues P., Garrido M., Alazzouzi H., Nieto R.,
RA   Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.;
RT   "Highly expressed genes in rapidly proliferating tumor cells as new
RT   targets for colorectal cancer treatment.";
RL   Clin. Cancer Res. 21:3695-3704(2015).
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
RX   PubMed=26537799; DOI=10.1074/mcp.M115.051235;
RA   Holst S., Deuss A.J.M., van Pelt G.W., van Vliet S.J.,
RA   Garcia-Vallejo J.J., Koeleman C.A.M., Deelder A.M., Mesker W.E.,
RA   Tollenaar R.A.E.M., Rombouts Y., Wuhrer M.;
RT   "N-glycosylation profiling of colorectal cancer cell lines reveals
RT   association of fucosylation with differentiation and caudal type
RT   homebox 1 (CDX1)/villin mRNA expression.";
RL   Mol. Cell. Proteomics 15:124-140(2016).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=26869432; DOI=10.1016/j.xphs.2015.10.030;
RA   Olander M., Wisniewski J.R., Matsson P., Lundquist P., Artursson P.;
RT   "The proteome of filter-grown Caco-2 cells with a focus on proteins
RT   involved in drug disposition.";
RL   J. Pharm. Sci. 105:817-827(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=28683746; DOI=10.1186/s12943-017-0691-y;
RA   Berg K.C.G., Eide P.W., Eilertsen I.A., Johannessen B., Bruun J.,
RA   Danielsen S.A., Bjornslett M., Meza-Zepeda L.A., Eknaes M., Lind G.E.,
RA   Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.;
RT   "Multi-omics of 34 colorectal cancer cell lines -- a resource for
RT   biomedical studies.";
RL   Mol. Cancer 16:116.1-116.16(2017).
RX   PubMed=29101300; DOI=10.15252/msb.20177701;
RA   Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S.,
RA   Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S.,
RA   Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J.,
RA   Weichert W., Knapp S., Feller S.M., Kuster B.;
RT   "Pharmacoproteomic characterisation of human colon and rectal
RT   cancer.";
RL   Mol. Syst. Biol. 13:951-951(2017).
RX   PubMed=29787057; DOI=10.1007/978-3-319-16104-4_10;
RA   Lea T.;
RT   "Caco-2 cell line.";
RL   (In) The impact of food bioactives on health. In vitro and ex vivo models; Verhoeckx K., Cotter P., Lopez-Exposito I., Kleiveland C., Lea T., Mackie A., Requena T., Swiatecka D., Wichers H. (eds.); pp.103-111; Springer; Cham (2015).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31981602; DOI=10.1016/j.tiv.2020.104773;
RA   O'Doherty C., Keenan J., Henry M., Meleady P., Sinkunaite I.,
RA   Clynes M., O'Sullivan F., Horgan K., Murphy R.;
RT   "Characterisation and proteomic profiling of continuously exposed
RT   Cu-resistant variants of the Caco-2 cell line.";
RL   Toxicol. In Vitro 65:104773.1-104773.14(2020).
RX   PubMed=33389257; DOI=10.1007/s10096-020-04106-0;
RA   Wurtz N., Penant G., Jardot P., Duclos N., La Scola B.;
RT   "Culture of SARS-CoV-2 in a panel of laboratory cell lines,
RT   permissivity, and differences in growth profile.";
RL   Eur. J. Clin. Microbiol. Infect. Dis. 40:477-484(2021).
RX   PubMed=34339474; DOI=10.1371/journal.pone.0255622;
RA   Pommerenke C., Rand U., Uphoff C.C., Nagel S., Zaborski M., Hauer V.,
RA   Kaufmann M., Meyer C., Denkmann S.A., Riese P., Eschke K., Kim Y.,
RA   Safranko Z.M., Kurolt I.-C., Markotic A., Cicin-Sain L., Steenpass L.;
RT   "Identification of cell lines CL-14, CL-40 and CAL-51 as suitable
RT   models for SARS-CoV-2 infection studies.";
RL   PLoS ONE 16:E0255622-E0255622(2021).